Federated Hermes
RARE icon

Federated Hermes’s Ultragenyx Pharmaceutical RARE Stock Holding History

Federated Hermes’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-496,060
Closed -$14.9M – 2182
2025
Q3 		$14.9M Sell
496,060
-1,553,441
-76% -$46.6M 0.03% 475
2025
Q2 		$74.5M Sell
2,049,501
-5,699
-0.3% -$205K 0.14% 180
2025
Q1 		$74.4M Buy
2,055,200
+5,400
+0.3% +$225K 0.16% 164
2024
Q4 		$86.2M Sell
2,049,800
-60,900
-3% -$3.02M 0.19% 141
2024
Q3 		$117M Buy
2,110,700
+3,675
+0.2% +$187K 0.26% 91
2024
Q2 		$86.6M Buy
2,107,025
+168,345
+9% +$7.19M 0.21% 117
2024
Q1 		$90.5M Sell
1,938,680
-507,820
-21% -$24M 0.21% 124
2023
Q4 		$117M Buy
2,446,500
+250,000
+11% +$9.69M 0.29% 76
2023
Q3 		$78.3M Buy
2,196,500
+419,900
+24% +$16.6M 0.21% 118
2023
Q2 		$82M Sell
1,776,600
-749,000
-30% -$34.7M 0.2% 108
2023
Q1 		$101M Sell
2,525,600
-568,900
-18% -$24.4M 0.25% 85
2022
Q4 		$143M Sell
3,094,500
-721,897
-19% -$28.4M 0.4% 49
2022
Q3 		$158M Buy
3,816,397
+19,308
+0.5% +$992K 0.46% 41
2022
Q2 		$227M Sell
3,797,089
-190,639
-5% -$11.7M 0.62% 28
2022
Q1 		$290M Buy
3,987,728
+858
+0% +$59.7K 0.65% 21
2021
Q4 		$335M Sell
3,986,870
-162
-0% -$13.2K 0.62% 19
2021
Q3 		$360M Buy
3,987,032
+135,722
+4% +$12.3M 0.68% 18
2021
Q2 		$367M Sell
3,851,310
-61,098
-2% -$6.37M 0.68% 18
2021
Q1 		$445M Sell
3,912,408
-368,120
-9% -$50.1M 0.86% 11
2020
Q4 		$593M Buy
4,280,528
+186,213
+5% +$22.1M 1.21% 3
2020
Q3 		$337M Buy
4,094,315
+13,956
+0.3% +$1.16M 0.79% 17
2020
Q2 		$319M Buy
4,080,359
+63,599
+2% +$4.21M 0.79% 20
2020
Q1 		$178M Buy
4,016,760
+1,044,752
+35% +$54.2M 0.52% 34
2019
Q4 		$127M Buy
2,972,008
+117,698
+4% +$4.86M 0.28% 76
2019
Q3 		$122M Buy
2,854,310
+1,079,658
+61% +$58.7M 0.3% 68
2019
Q2 		$113M Buy
1,774,652
+25,378
+1% +$1.62M 0.27% 78
2019
Q1 		$121M Buy
1,749,274
+471,955
+37% +$27M 0.3% 68
2018
Q4 		$55.5M Sell
1,277,319
-206,952
-14% -$11.3M 0.15% 140
2018
Q3 		$113M Buy
1,484,271
+66,720
+5% +$5.43M 0.26% 79
2018
Q2 		$109M Buy
1,417,551
+218,060
+18% +$14.1M 0.32% 73
2018
Q1 		$61.2M Buy
1,199,491
+98,691
+9% +$4.97M 0.18% 111
2017
Q4 		$51.1M Buy
1,100,800
+709,200
+181% +$34.8M 0.14% 124
2017
Q3 		$20.9M Sell
391,600
-25,500
-6% -$1.51M 0.06% 253
2017
Q2 		$25.9M Hold
417,100
– – 0.07% 231
2017
Q1 		$28.3M Sell
417,100
-21,200
-5% -$1.62M 0.08% 214
2016
Q4 		$30.8M Sell
438,300
-4,300
-1% -$305K 0.09% 184
2016
Q3 		$31.4M Sell
442,600
-450
-0.1% -$28.7K 0.09% 177
2016
Q2 		$21.7M Hold
443,050
– – 0.06% 255
2016
Q1 		$28M Buy
443,050
+43,250
+11% +$2.83M 0.09% 200
2015
Q4 		$44.9M Buy
399,800
+650
+0.2% +$65K 0.14% 142
2015
Q3 		$38.4M Buy
399,150
+550
+0.1% +$63K 0.12% 168
2015
Q2 		$40.8M Hold
398,600
– – 0.12% 177
2015
Q1 		$24.7M Buy
398,600
+109,700
+38% +$6.09M 0.08% 251
2014
Q4 		$12.7M Hold
288,900
– – 0.04% 393
2014
Q3 		$16.4M Buy
288,900
+150,000
+108% +$7.55M 0.05% 327
2014
Q2 		$6.24M Sell
138,900
-2,400
-2% -$98.8K 0.02% 585
2014
Q1 		$6.91M Buy
+141,300
New +$7.27M 0.02% 562

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Federated Hermes's RARE Position: Q4 2025 in Review

Federated Hermes sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 496,060 shares — an estimated $14.9M sold.

Federated Hermes first reported a position in RARE in Q1 2014 and held it in 47 quarters. The position peaked at $593M in Q4 2020. 287 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

  • Federated Hermes reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Federated Hermes sold 496,060 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $14.9M.
  • Federated Hermes first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 47 quarters.
  • Federated Hermes's Ultragenyx Pharmaceutical position peaked at $593M in Q4 2020.
  • 287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Federated Hermes's 13F filing for Q4 2025, filed 12 Feb 2026.